Aktis Oncology, Inc. (AKTS) — Analyst outlook / Analyst consensus target is. Based on 7 analyst ratings, the consensus is bullish — 4 Buy, 3 Hold.
The consensus price target is $31.00, representing an upside of 73.8% from the current price $17.84.
Analysts estimate Earnings Per Share (EPS) of $-0.71 and revenue of $0.03B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-1.89 vs est $-0.71 (missed -167.1%). Analyst accuracy: 37%.
AKTS Stock — 12-Month Price Forecast
$31.00
▲ +73.77% Upside
Average Price Target
Based on 7 Wall Street analysts offering 12-month price targets for Aktis Oncology, Inc., the price target is $31.00.
The average price target represents a +73.77% change from the last price of $17.84.
AKTS Analyst Ratings
Buy
Based on 7 analysts giving stock ratings to Aktis Oncology, Inc. in the past 3 months
EPS Estimates — AKTS
37%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024
Actual –$1.89
vs Est –$0.71
▼ 62.6% off
2025
Actual $0.00
vs Est –$0.25
▲ 0.0% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS trend is improving.
Revenue Estimates — AKTS
0%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024
Actual $0.027B
vs Est $0.029B
▼ 5.3% off
2025
Actual $0.006B
vs Est $0.040B
▼ 515.7% off
Revenue Trend
Revenue has declined over the period shown. Analysts forecast significant revenue growth ahead.
